Patents by Inventor Yoshiki Sakai
Yoshiki Sakai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082154Abstract: The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.Type: ApplicationFiled: October 23, 2023Publication date: March 14, 2024Inventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
-
Publication number: 20210113464Abstract: The present invention provides a clinically applicable, safe and convenient, pharmaceutical composition for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.Type: ApplicationFiled: November 27, 2017Publication date: April 22, 2021Inventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
-
Publication number: 20200360391Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.Type: ApplicationFiled: June 1, 2020Publication date: November 19, 2020Applicants: Osaka University, Cardio IncorporatedInventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
-
Publication number: 20190343841Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.Type: ApplicationFiled: December 27, 2017Publication date: November 14, 2019Applicants: Osaka University, Cardio IncorporatedInventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
-
Publication number: 20180357669Abstract: A system according to one aspect of the present disclosure comprises an acquisition unit, a determination unit, and an output unit. The acquisition unit acquires a list of consumers selected from a first consumer group. The determination unit determines, based on first and second databases, consumers in a second consumer group at least similar in feature to the consumers represented in the list as targets. The first and the second databases respectively represent features related to consumption behavior of each of consumers belonging to the first and the second consumer groups. The output unit outputs data representing one of tendency or behavior history of the targets.Type: ApplicationFiled: November 18, 2016Publication date: December 13, 2018Inventors: Shinya Tokuhisa, Toshihiro Tsujita, Kaho Okuno, Yoshiki Sakai
-
Patent number: 9968716Abstract: The present invention provides a drug-eluting stent graft for preventing stent graft-related complications as well as treating aneurysm. Specifically, the present invention relates to a drug-eluting stent graft comprising a drug, a drug-retaining agent and a stent graft, and a method for therapy of aneurysm including the use of the drug-eluting stent graft.Type: GrantFiled: September 10, 2014Date of Patent: May 15, 2018Assignees: ONO PHARMACEUTICAL CO., LTD., OSAKA UNIVERSITYInventors: Yoshiki Sawa, Toru Kuratani, Koichi Toda, Takayoshi Ueno, Shigeru Miyagawa, Satsuki Fukushima, Atsuhiro Saito, Yoshiki Watanabe, Yoshiki Sakai
-
Patent number: 9597436Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.Type: GrantFiled: September 13, 2013Date of Patent: March 21, 2017Assignees: Osaka University, Nipro Corporation, Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sawa, Shigeru Miyagawa, Satsuki Fukushima, Atsuhiro Saito, Yoshiki Sakai, Kazuhisa Matsuda, Takayuki Maruyama
-
Publication number: 20160250395Abstract: The present invention provides a drug-eluting stent graft for preventing stent graft-related complications as well as treating aneurysm. Specifically, the present invention relates to a drug-eluting stent graft comprising a drug, a drug-retaining agent and a stent graft, and a method for therapy of aneurysm including the use of the drug-eluting stent graft.Type: ApplicationFiled: September 10, 2014Publication date: September 1, 2016Inventors: Yoshiki Sawa, Toru Kuratani, Koichi Toda, Takayoshi Ueno, Shigeru Miyagawa, Satsuki Fukushima, Atsuhiro Saito, Yoshiki Watanabe, Yoshiki Sakai
-
Publication number: 20150272874Abstract: An object of the present invention is to provide a lung-specific therapeutic agent that can be intravenously administered. The present invention provides a lung-specific therapeutic agent characterized by containing sustained-release microspheres that contain a pharmaceutical compound and being intravenously administered.Type: ApplicationFiled: October 28, 2013Publication date: October 1, 2015Inventors: Yoshiki Sawa, Shigeru Miyagawa, Masaki Taira, Yoshiki Sakai
-
Publication number: 20150231312Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.Type: ApplicationFiled: September 13, 2013Publication date: August 20, 2015Inventors: Yoshiki Sawa, Shigeru Miyagawa, Satsuki Fukushima, Atsuhiro Saito, Yoshiki Sakai, Kazuhisa Matsuda, Takayuki Maruyama
-
Patent number: 8642630Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: GrantFiled: April 4, 2013Date of Patent: February 4, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sakai, Akio Nishiura, Teppei Ogata
-
Patent number: 8617614Abstract: The present invention provides a microsphere with a slow-release period from about two weeks to about four weeks following administration, to enable a higher content of a drug to be included, to suppress an initial burst of the drug, and to maintain an optimal, effective blood concentration during the slow-release period. In a microsphere containing a drug and polylactic acid/glycolic acid (PLGA) copolymer, the amount of PLGA copolymer per part by weight of the drug is from about 3 to about 10 parts by weight; the average particle size of the microsphere is from about 20 to about 50 ?m; and (3) the PLGA copolymer has a weight-average molecular weight from about 10,000 to about 50,000 and a PLGA compositional ratio from about 75/25 to about 50/50. The microsphere promotes the production of various endogenous repair factors useful against various tissue disorders.Type: GrantFiled: October 18, 2007Date of Patent: December 31, 2013Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sakai, Takahiro Uchida
-
Patent number: 8436026Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: GrantFiled: February 20, 2008Date of Patent: May 7, 2013Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sakai, Akio Nishiura, Teppei Ogata
-
Publication number: 20110071204Abstract: This present invention provides a percutaneous absorption type pharmaceutical preparation which includes 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the active ingredient and a backbone for transdermal system, and satisfies at least one of the following conditions (1) and (2). The pharmaceutical preparation of the present invention enables absorption of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide, which has a low ability to be absorbed from the skin, from the skin into the body continuously and efficiently. (1) The active ingredient content in one preparation or one time administration preparation is from about 0.1 mg to about 10 mg, (2) the size is from about 1 cm2 to about 300 cm2.Type: ApplicationFiled: February 2, 2006Publication date: March 24, 2011Applicants: KYORIN PHARMACEUTICAL CO., LTD., ONO PHARMACEUTICAL CO., LTD.Inventors: Koichi Takahashi, Yoshiki Sakai
-
Publication number: 20100323026Abstract: The object of the present invention is to provide a microsphere which has a slow-release period of from about two weeks to about four weeks following administration, enables a higher content of a drug to be included, suppresses an initial burst of the drug, and enables the drug to be maintained at an optimal, effective blood concentration during the slow-release period. In a microsphere containing a drug and PLGA, the above problems can be resolved by setting: (1) the amount of lactic acid/glycolic acid copolymer per part by weight of the drug to from about 3 to about 10 parts by weight; (2) the microsphere to an average particle size of from about 20 to about 50 ?m; and (3) the lactic acid/glycolic acid copolymer to a weight-average molecular weight of from about 10,000 to about 50,000 and to a lactic acid/glycolic acid compositional ratio of from about 75/25 to about 50/50.Type: ApplicationFiled: October 18, 2007Publication date: December 23, 2010Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Yoshiki Sakai, Takahiro Uchida
-
Patent number: 7671057Abstract: The problem of the present invention is to provide a preventive and/or therapeutic agent for diabetes and/or complications of diabetes based on the novel mode of action. The protease-inhibiting compound according to the present invention is a compound represented by the general formula (I) [wherein all the symbols have the same meanings as described in the specification], its salt or solvate, or a prodrug thereof, is useful as a preventive and/or therapeutic agent for diabetes and/or complications of diabetes.Type: GrantFiled: November 7, 2005Date of Patent: March 2, 2010Assignee: Ono Pharmaceutical Co., Ltd.Inventor: Yoshiki Sakai
-
Publication number: 20090239828Abstract: The present invention provides an adhesive preparation having a plaster layer disposed on a support, the adhesive preparation comprising at least one active ingredient selected from the group consisting of a bisphosphonic acid derivative, its salt thereof and a hydrate of either of the bisphosphonic acid derivative or the salt, a solubilizer for the active ingredient, propylene glycol, a hydrogenated terpene resin, an adhesive base, and a softening agent in the plaster layer.Type: ApplicationFiled: September 10, 2007Publication date: September 24, 2009Inventors: Yuuhiro Yamazaki, Noriyuki Hayashi, Yoshiki Sakai
-
Patent number: 7547715Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: GrantFiled: October 9, 2003Date of Patent: June 16, 2009Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sakai, Akio Nishiura, Teppei Ogata
-
Publication number: 20080299089Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: ApplicationFiled: February 20, 2008Publication date: December 4, 2008Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Yoshiki SAKAI, Akio Nishiura, Teppei Ogata
-
Publication number: 20080009537Abstract: The problem of the present invention is to provide a preventive and/or therapeutic agent for diabetes and/or complications of diabetes based on the novel mode of action. The protease-inhibiting compound according to the present invention is a compound represented by the general formula (I) [wherein all the symbols have the same meanings as described in the specification], its salt or solvate, or a prodrug thereof, is useful as a preventive and/or therapeutic agent for diabetes and/or complications of diabetes.Type: ApplicationFiled: November 7, 2005Publication date: January 10, 2008Inventor: Yoshiki Sakai